Clinical trials: Lobular Breast Carcinoma
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC)
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of [68Ga]Ga-DFC413, and in Part 2 compare to [68Ga]Ga-NNS309 in patients with locally advanced or…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC)
- Trial name
- NCT07630961
- Testing
- 68Ga-DFC413, 68Ga-NNS309
- Where
- 2 sites in Denmark, Japan
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
*REFERRALS TO THIS TRIAL MUST BE THROUGH BREAST CARE CLINICIANS ONLY* RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ.
- Trial name
- NCT00804128
- Testing
- Magnetic Resonance Imaging (MRI), Gadavist
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Precancerous Condition
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
RATIONALE: Broccoli sprout extract supplements may slow the growth of tumor cells or abnormal cells and may be an effective treatment for ductal carcinoma in situ and/or atypical ductal hyperplasia.
- Trial name
- NCT00843167
- Testing
- broccoli sprout extract
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
This phase II trial studies how well radiation therapy works in treating post-menopausal women with early stage breast cancer undergoing surgery. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT01754519
- Testing
- Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
DCIS
Evaluation of the DCIS Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS
To evaluate whether the use of the Oncotype DX DCIS score can guide delivery of radiation in women with low to moderate risk DCIS who have had breast conserving surgery
- Trial name
- DUCHESS (NCT02766881)
- Where
- 12 sites in Canada
- Volunteers
- 281 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Carcinoma, Lobular
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma
This study aims to explore the diagnostic validity of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with invasive lobular breast cancer having clinically suspected or confirmed axillary lymph…
- Trial name
- NCT05960201
- Testing
- [18F]fluoroestradiol (FES)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Asan Medical Center
Breast Cancer
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.
- Trial name
- NCT00054301
- Testing
- adjuvant therapy, conventional surgery, intraoperative radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Ductal Carcinoma In Situ
Hong Kong Breast Cancer Study
Introduction: With population ageing and increasing Westernization breast cancer continues to be important health conditions among women in Hong Kong.
- Trial name
- NCT02889458
- Testing
- Not Provided
- Where
- 21 sites in Hong Kong
- Volunteers
- 7,000 people
- Sponsor
- The University of Hong Kong
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer
This pilot research trial studies the effects of chemotherapy on intestinal bacteria/organisms (microbiota) in patients newly diagnosed with breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT02370277
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Southern California
Breast Cancer
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Estrogen can stimulate the growth of breast cancer cells.
- Trial name
- NCT00003857
- Testing
- tamoxifen citrate, adjuvant therapy, radiation therapy
- Where
- 369 sites in United States, Canada
- Volunteers
- 636 people
- Sponsor
- Radiation Therapy Oncology Group
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8
- Trial name
- NCT04959474
- Testing
- Best Practice, Stereotactic Body Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Thomas Jefferson University
Ductal Carcinoma in Situ
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
The purpose of this study is to find molecular signs (biomarkers) to better understand the role of green tea as an anti-cancer and anti-inflammation agent in women with newly-diagnosed ductal carcinoma in situ (DCIS).
- Trial name
- NCT01060345
- Testing
- Polyphenon E
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
DCIS, Ductal Carcinoma in Situ
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS.
- Trial name
- COMET (NCT02926911)
- Testing
- Surgery, Active Monitoring
- Where
- 141 sites in United States
- Volunteers
- 997 people
- Sponsor
- Alliance Foundation Trials, LLC.
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52).
- Conditions
- Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
- Trial name
- NCT02150525
- Testing
- omega-3 fatty acid, Questionnaire administration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ
- Trial name
- NCT06184750
- Testing
- Biopsy Procedure, Biospecimen Collection, Mammography
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Carcinoma in Situ
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Women with biopsy-proven ductal carcinoma in situ (DCIS) will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor or selective estrogen receptor modulator (SERM) for about 12…
- Trial name
- NCT06218303
- Testing
- MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Finn, Olivera, PhD
Ductal Carcinoma In Situ
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Primary Objectives: To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) To evaluate the effect of a single dose of Herceptin…
- Trial name
- NCT00496808
- Testing
- Herceptin (Trastuzumab)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Intraductal, Noninfiltrating
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.
- Trial name
- NCT02872025
- Testing
- Pembrolizumab, Intralesional mRNA 2752
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Laura Esserman
Breast Cancer
Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00960336
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- France
- Volunteers
- 59 people
- Sponsor
- ARCAGY/ GINECO GROUP